Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China To Tighten Control Over Stimulants

This article was originally published in PharmAsia News

Executive Summary

In China's continuous crack down on illegal production and trading of stimulants, China's State FDA, State Administration for Industry & Commerce, Ministry of Industry & Information Technology and Ministry of Public Security have jointly announced that effective June 19, all chemical companies should not produce or deal with prohibited substances in the catalog of stimulants without permission. Online advertising and sales of such products, including protein assimilation preparations and peptide hormones, are also strictly prohibited. China will further intensify inspection work: eight ministries including the Ministry of Health and SFDA will inspect the stimulant management of the six Olympics host cities from late June to early July; investigation and confirmation of contraband will lead to heavy prosecution; and telephone number and email address will be publicized for informants. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel